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Abstract
Background: Disseminated tumor cells (DTCs) found in the bone marrow (BM) of patients with breast cancer
portend a poor prognosis and are thought to be intermediaries in the metastatic process. To assess the clinical
relevance of a mouse model for identifying possible prognostic and predictive biomarkers of these cells, we have
employed patient-derived xenografts (PDX) for propagating and molecularly profiling human DTCs.
Methods: Previously developed mouse xenografts from five breast cancer patients were further passaged by
implantation into NOD/SCID mouse mammary fat pads. BM was collected from long bones at early, serial
passages and analyzed for human-specific gene expression by qRT-PCR as a surrogate biomarker for the
detection of DTCs. Microarray-based gene expression analyses were performed to compare expression profiles
between primary xenografts, solid metastasis, and populations of BM DTCs. Differential patterns of gene
expression were then compared to previously generated microarray data from primary human BM aspirates
from patients with breast cancer and healthy volunteers.
Results: Human-specific gene expression of SNAI1, GSC, FOXC2, KRT19, and STAM2, presumably originating from DTCs,
was detected in the BM of all xenograft mice that also developed metastatic tumors. Human-specific gene expression
was undetectable in the BM of those xenograft lines with no evidence of distant metastases and in non-transplanted
control mice. Comparative gene expression analysis of BM DTCs versus the primary tumor of one mouse line identified
multiple gene transcripts associated with epithelial-mesenchymal transition, aggressive clinical phenotype, and
metastatic disease development. Sixteen of the PDX BM associated genes also demonstrated a statistically
significant difference in expression in the BM of healthy volunteers versus the BM of breast cancer patients
with distant metastatic disease.
Conclusion: Unique and reproducible patterns of differential gene expression can be identified that presumably
originate from BM DTCs in mouse PDX lines. Several of these identified genes are also detected in the BM of patients
with breast cancer who develop early metastases, which suggests that they may be clinically relevant biomarkers. The
PDX model may also provide a clinically relevant system for analyzing and targeting these intermediaries of metastases.
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Background
Multiple prospective clinical trials have demonstrated
that disseminated tumor cells (DTCs) found in the bone
marrow (BM) of patients with early-stage breast cancer
are highly correlated with early recurrent disease devel-
opment and portend a poor prognosis [1, 2], even many
years after initial diagnosis [3]. BM DTCs are thought to
be intermediaries in the metastatic process, transitioning
in the BM, re-entering the circulation, and proliferating
in distant organs with a favorable molecular micro-
environment [4]. DTCs in the BM may be indicative of
the systemic burden of micrometastatic disease in the
patient [2]. Those patients with residual DTCs after
chemotherapy are at very high risk of recurrence, indi-
cating that those cells that survive chemotherapy have
high metastatic potential [5]. Recent animal models sug-
gest that early disseminated cells evolve in parallel to the
primary tumor and have high metastatic potential [6, 7].
To prevent the development of metastatic outgrowth, it
is necessary to devise therapeutic strategies to target the
intermediary cancer cells that evade conventional
treatment.
To date, primary DTCs have been difficult to
characterize. The rarity of these cells, the lack of uni-
form markers for detecting cells with metastatic poten-
tial, and the evolution of the cells while in a foreign
micro-environment are the main constraints in identify-
ing, isolating, and molecularly characterizing DTCs from
patient BM specimens [8]. To address these limitations,
we have investigated the use of patient-derived xenograft
mouse models (PDX), wherein primary human breast
carcinomas are transplanted and propagated in the
mammary fat pad of mice, as a continuous, reproducible
source of disseminated tumor cells for molecular
characterization. Multiple studies have documented that
the molecular profile, histopathological characteristics,
and therapeutic sensitivities of PDX tumors recapitulate
that of their primary tumor counterparts, and therefore
should serve as an excellent model for tracking, study-
ing, and testing interventions for metastatic disease
development [9–11]. Evidence from other studies shows
that primary, peripheral blood, circulating tumor cells
(CTCs) from patients with breast cancer can also survive
and propagate as mouse xenografts, again suggesting
phenotypic parallels between PDX and human metasta-
ses [12, 13]. Recently, detection of CTCs and DTCs has
been reported in a PDX model [14].
In this report, using a PDX system established by
transplanting primary tumors from pre-metastatic
patients with breast cancer, we demonstrate that devel-
opment of distant organ metastases correlates with the
presence of BM DTCs. Comparative gene expression
analysis of BM from these animals has allowed the iden-
tification of novel gene expression patterns associated
with DTC colonization of BM and further supports the
concept that DTCs present in the BM undergo epithelial
to mesenchymal transition (EMT). Moreover, the ex-
pression of many of the genes identified in this PDX
model distinguish BM from patients with breast cancer
who develop early metastatic relapse from that of
healthy female volunteers, suggesting potential value as
prognostic and predictive biomarkers. We believe that
the PDX model is an effective tool to identify and study
the molecular characteristics of BM DTCs and their role
in the metastatic process, and should allow for the de-
velopment of new therapies to target these cells.
Methods
Patient population and establishment of PDX lines
After patients gave informed consent, human breast
adenocarcinomas were prospectively collected using a
protocol approved by the Institutional Review Board at
Washington University in St. Louis, and transplanted
into mice. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use
Committee at Washington University in St. Louis.
Briefly, after 3-week old female NOD-SCID mice were
anesthetized, an inverted Y-shaped incision was made to
expose the mammary glands. Using a dissecting micro-
scope, the lymph-node and the vessel in the fat bridge
between the fourth and fifth mammary fat pads were
cauterized. The breast epithelium in this area was then
excised to create the “cleared fat pad” into which human
breast tissues were implanted without interference from
the host’s mammary epithelium. At 2 weeks post clear-
ance, 500,000 immortalized green fluorescent protein
(GFP)-labeled human breast fibroblasts were injected
into each cleared fat pad. After an additional 2 weeks,
the humanized fat pads received tumor implants. Breast
biopsies were prepared for engraftment by placing tissue
in ice-chilled high glucose DMEM, immediately trans-
porting it to the laboratory, and mincing into 1–2-mm
pieces for implantation in up to five mice. Further details
of the development and maintenance of xenograft lines
has been previously described [9–11]. Individual animals
are designated using the labeling convention: primary
tumor line – passage – unique animal ID (e.g. 17-B-
1141). Clinical features and pathological characteristics
of the five patient tumor xenograft lines that were used
for the present studies are listed in Table 1.
BM and RNA isolation
Mice were killed when the primary xenograft tumor
reached approximately 1.5 cm in size (approximately 6–
8 weeks after implanting the tumor tissues). The femur
and tibia were dissected from surrounding tissue, avoid-
ing potential contamination, and flushed with cold PBS
to isolate BM cells. Normal mouse BM samples were
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collected from non-tumor-bearing NOD-SCID mice,
both with and without transplanted human fibroblasts.
BM from the four long bones of each animal was pooled
and cells pelleted for RNA extraction. Total RNA was
isolated from samples using Trizol reagent (Invitrogen)
according to manufacturer’s protocol. The extracted
RNA was quantified and qualitatively assessed using an
Agilent Bioanalyzer.
qRT-PCR
One microgram of RNA was used for synthesis of first-
strand complementary DNA (cDNA) using the Retro-
script (Ambion) kit with random hexamers. Resulting
cDNA was diluted to an equivalent of 10 ng/μL of input
RNA. qRT-PCR of the indicated genes was performed as
described previously [8]. Human specific primer/probe
sets for the genes tested were purchased from Applied
Biosystems and the assay ids of the probes used are
given in Additional file 1: Table S1. Each reaction con-
sisted of 2 μL of cDNA, TaqMan Master Mix (Applied
Biosystems) and primer/probe set in a total volume of
20 μL. For each transcript/sample, triplicate reactions
were run in an ABI 7500 FAST Sequence Detection
System. If a transcript was not detected in at least two
replicates by cycle 40, it was considered absent in that
sample and excluded from further analysis. Reactions
with a cycle threshold (CT) value difference >1.5 for the
same probe were also excluded from further analysis.
The CT values of each gene were normalized to mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
CT values for the same sample. These delta CT (dCT)
values were then normalized to corresponding dCT
values of the non-tumor-bearing mice for the same tran-
script and fold change calculated using the ddCT
method. Transcripts that did not reach CT in non-
tumor-bearing control mouse samples after 40 cycles
were assigned a CT value of 40 for calculation purposes.
Microarray analysis
Gene expression profiling was performed as previously
described [8]. Total RNA was used for two-cycle bio-
tinylated cRNA target synthesis (Affymetrix). Resulting
biotinylated cRNA was quantified and samples that
yielded >15 μg of cRNA were used for GeneChip micro-
array hybridization. Fragmented, biotinylated cRNAs
were hybridized to Affymetrix Human Gene 1.0 ST
microarrays following standard protocols. Arrays were
hybridized, washed, and scanned following the
Table 1 Clinical details and pathological characteristics of tumor specimens used for generating the PDX WHIM lines, as determined
and further described in a previous publication [11]



















262 ER+/HER2- Luminal-B Breast BN, CNS 37 11 11E 1221 ER+/HER2- None






270 ER-/HER2- Basal Chest wall BR, CT, L, H, BN 44+ b 13 13A 1204 ER-/PR- None
7192 ER-/HER2- Claudin-low Breast None 37+ b 17 17A 1384 ER-/HER2- H, N
17B 1139 ER-/HER2- H
17B 1141 L
17B1188 L, H
17B29 L, H, S
17C1180 ER-/HER2- L
17C1182 L, H, S, K
319 ER+/HER2- Luminal-B Skin CT, N 97 23 23C 1832 None
23C 1833 ER+/HER2- None
23C 1834 None
Individual mice used for bone marrow analysis are designated by: WHIM line number - passage number – unique mouse ID
Abbreviations: PDX patient-derived xenograft, WHIM Washington University Human in Mouse ER estrogen receptor, HER2 human epidermal growth factor receptor
2, BR breast, CNS brain, BN bone, L lung, CT cutaneous, PL pleura, PC pericardium, N nodes, H liver, S spleen, K kidney, PR progesterone receptor
bAlive at last follow up
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manufacturer's protocol. GeneChip CEL files were proc-
essed with the RMA algorithm and normalized using
Partek Genomics Suite software. Differential patterns of
gene expression were identified from annotated, normal-
ized microarray data as detailed in the “Results” section.
All data filtering, visualization, and analysis of variance
(ANOVA) was performed using Partek Genomics Suite
software. A schematic of data sets utilized and analysis
workflows are presented in Fig. 1. Gene expression data are
available at Gene Expression Omnibus [GEA:GSE57947].
Results
Development of metastatic tumors correlates with
presence of human cells in mouse BM
To investigate the clinical relevance of PDX models for
studying BM DTCs in patients with breast cancer, we
utilized a set of previously characterized PDX mouse
lines [9, 11, 15]. BM was collected from a total of 18 ani-
mals, spanning five different passages and representing
initial implants from five different patients with a variety
of molecular phenotypes (Table 1). All but one patient
(7192) developed distant, clinical metastatic disease.
To allow for multiple molecular analyses with limited
amounts of BM, we employed a molecular screen to
detect BM DTCs in each animal, based on detection of
human-specific GAPDH (hGAPDH) transcript. As
shown in Fig. 2a, 10 of 18 (55%) animals analyzed had
detectable expression of hGAPDH in their BM.
hGAPDH expression clearly emanated from BM DTCs
as other humanized xenograft animals and non-grafted
controls, but fat pad humanized animals, had no detect-
able expression of hGAPDH (data not shown). Further-
more, all BM samples were assayed for GFP gene
expression and found to be negative (data not shown),
suggesting that hGAPDH expression emanated from
actual DTCs and not from the GFP-labelled human
fibroblasts that were implanted and that may have mi-
grated from fat pad implantation. Although the actual
number of human DTCs present in the BM of each
mouse could not be calculated based on qRT-PCR data,
assuming that hGAPDH expression levels per input mass
of total RNA are proportional to DTC cell numbers, it is
clear that WHIM17 mice maintained a much higher
tumor burden in their BM, as compared to those from
the WHIM12 line (Fig. 2a).
Among the DTC-positive mice, seven originated from
the WHIM17 line and three originated from the
WHIM12 line. These ten animals all developed distant
solid metastases, primarily to the lung and liver (Table 1).
In contrast, eight other animals, originating from lines
WHIM11, WHIM12, WHIM13, and WHIM23 had nei-
ther detectable expression of hGAPDH in their BM nor
any evidence of distant solid metastases, even after pri-
mary tumor growth had progressed to 1.5 cm at their
greatest diameter at the time of sacrifice. The presence
of BM DTCs and the development of distant metastases
Fig. 1 Data sets, analyses, and workflows utilized for identifying disseminated tumor cell gene expression biomarkers. BM bone marrow, Met
metastasis, BRCA breast cancer, WHIM Washington University Human in Mouse
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were highly correlated (p < 0.0001, Fisher’s exact test),
consistent with clinical observations of DTCs and meta-
static disease development in patients [1, 8]. In fact,
although only 18 animals were analyzed in this study,
detection of hGAPDH expression in BM was 100% spe-
cific and 100% sensitive for predicting metastatic spread
of the xenograft tumor.
Human DTCs in mouse BM express markers of epithelial-
mesenchymal transition (EMT)
Data suggest that only those cancer cells that undergo ex-
tensive molecular and phenotypic adaptations, such as
EMT, will successfully survive and proliferate in a foreign
micro-environment [16]. We therefore examined the BM of
the PDX mice for the expression of genes associated with
both epithelial cell lineage and EMT using directed, qRT-
PCR analyses for human-specific gene expression. EMT-
associated transcripts included Snail1 (SNAI1), Gooscoid
(GSC), and FOXC2. As expected, in control and non-
metastatic mice without hGAPDH expression in BM, none
of the epithelial and EMT marker genes were detected. In
eight of the ten hGAPDH-positive mice, epithelial marker
genes often used for DTC detection in human studies, i.e
keratin17 (KRT17), mammaglobin (SCGB2A2), and EpCAM
(TACSTD1) were also not detected. Keratin19 (KRT19) ex-
pression was detected in only one animal derived from the
WHIM17 line (i.e. 17-B-1141). In contrast, expression of
three EMT marker transcripts, Snail1 (SNAI1), Gooscoid
(GSC), and FOXC2 were detected in many, albeit not all, of
the seven WHIM17-derived animals (Fig. 2b) but in none of
the WHIM12 mice. Since hGAPDH expression in the
WHIM12 animals was also lower, this may simply reflect
lower tumor (DTC) burden in the BM of these animals.
Comparative molecular profiles of DTCs and their
corresponding primary and metastatic tumors
To better understand the molecular evolution of tumor
metastasis we utilized one PDX line (WHIM17) to
Fig. 2 Expression of human-specific GAPDH (hGAPDH) (a) and other biomarker genes of epithelial cell lineage and epithelial to mesenchymal
transition (b), detected in the bone marrow (BM) of patient-derived xenograft (PDX) mice. Expression of each transcript in the BM of tumor
bearing mice is represented relative to that in non-tumor-bearing humanized NOD-SCID mice (control), using the dd CT method. Since human-specific
transcripts were not detected in the BM of control mice, for calculation purposes, a CT value of 40 was assigned. *Animals that developed metastatic
tumors. The association between metastatic outcome and gene expression was statistically significant for hGAPDH (p < 0.0001), STAM2 (p = 0.004),
DSCR3 (p = 0.004) and FOXC2 (p = 0.036) analyzed by the Fisher exact test
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compare patterns of gene expression between primary
xenograft tumor, BM DTC populations, and distant solid
organ metastasis. Of specific interest were patterns of
gene expression that were unique to DTC populations,
and groups of genes that were common to both DTCs
and solid organ metastasis, but distinct from those of
the primary tumor itself.
Gene expression microarray analysis was performed
on the WHIM17 primary xenograft tumor (17-B-29),
a splenic metastasis that developed in that animal
(17-B-29), and one DTC-positive BM sample from the
same animal and six from different passages from the
same line. Although human-specific microarrays were
used for this analysis, it was expected that some
patterns of gene expression in the mouse BM samples
could originate from cross-hybridization of transcripts
from murine BM cells. Therefore, we also profiled
two BM samples from both control mice and non-
engrafted mice with humanized mammary fat pads.
Expression data from these animals was used as a
baseline to identify human DTC-specific expression in
the BM of each of the WHIM17 animals. To validate
this in silico approach, we selected six transcripts of
genes previously implicated in tumorigenesis and me-
tastasis [17–26] the expression of which was elevated
at least threefold in all seven WHIM BM samples, as
compared to control BM, and confirmed expression
using human-specific primers and qRT-PCR (Fig. 3,
Additional file 2: Table S2).
GLN3, ITGB3BP, MALAT1, and ITGB1BP1 were de-
tected in the BM specimens from all WHIM17-derived
mice, but not in the BM of mice derived from any other
line. CD44 and ALCAM expression was detected in both
mice that developed (WHIM17 and WHIM12) and mice
that did not develop (WHIM23) metastatic disease.
None of the non-tumor-bearing control mice with hu-
manized mammary fat pads demonstrated expression of
any of these genes (Fig. 3).
As shown in Fig. 4, global gene expression analysis of
seven WHIM17 BM samples and corresponding tumor
and metastatic lesion from the WHIM 17B29 animal
showed specific clusters of genes with upregulated
expression in both the primary tumor and the metastatic
lesion. Surprisingly, there was considerable variability in
gene expression among BM samples from the WHIM17
animals that appeared independent of tumor passage,
pattern of metastatic spread, RNA quality, or other tech-
nical parameters. Not surprisingly, the WHIM17B29 BM
expressed the greatest resemblance to the primary and
metastatic lesion from the same animal, while four other
BM samples shared a unique profile with a large number
of transcripts that were over represented compared to
primary tumor, metastasis, or other hGAPDH-positive
BM samples.
We focused on clusters of 1979 unique “BM-specific”
and 394 unique “metastasis-specific” transcripts to iden-
tify those that may be most relevant as biomarkers for
the presence of DTCs. Additional file 3: Table S3 pro-
vides a complete list of those transcripts with signifi-
cantly different expression between DTCs and primary
tumors, and metastasis and primary tumor, while
Tables 2 and 3 provide further filtered lists of those
Fig 3 Validation of expressed genes identified from microarray analysis of Washington University Human in Mouse (WHIM)17 bone marrow (BM)
samples, by qRT-PCR. Expression of each transcript in the BM of tumor-bearing mice is represented relative to that in non-tumor-bearing humanized NOD-
SCID mice (control), using the dd CT method. Since human-specific transcripts were not detected in the BM of control mice, for calculation purposes, a CT
value of 40 was assigned. *Animals that developed metastatic tumors. The association between metastatic outcome and gene expression was statistically
significant for ALCAM (p= 0.013), GNL3 (p= 0.004), ITGB1BP1 (p= 0.004). ITGB3BP (p= 0.004), MALAT1 (p= 0.023 and CD44 (p= 0.004) analyzed by the Fisher
exact test
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transcripts most highly associated with “metastasis” in
the published literature in a comparison between metas-
tases versus primary tumor and BM versus primary
tumor. Many of these genes could be therapeutically tar-
geted and are at different stages of clinical development
(Tables 2 and 3). SLPI is appears in both gene sets indi-
cating its enhanced expression in DTCs as well as meta-
static tumor.
The molecular profiles of PDX DTCs are also found in BM
from patients with breast cancer
Since gene expression patterns strongly suggested that
cells in PDX mouse BM are derived from their primary
xenograft tumor, and that there is a robust association
between their presence and metastatic outcome, we next
investigated whether gene expression in the BM of
mouse PDX models could also be detected in the BM of
patients with breast cancer, prior to the development of
overt metastatic disease. Using previously generated BM
gene expression microarray data from a cohort of
treatment-naïve, clinical stage II/III patients with breast
cancer and healthy female controls [8], we examined the
expression of 420 unique genes from the PDX BM data
set to determine whether they could detect differences
between these populations. From the original set of 1979
“BM-specific” transcripts identified in the xenograft
model, we derived a set of 420 transcripts that both
could be mapped to human microarray expression data
probe sets and that were annotated in PubMed citations
with the key words “metastasis”, “invasion”, and “epithe-
lial mesenchymal transition” (Fig. 1). Globally (Fig. 5)
the WHIM17 BM gene set did not distinguish healthy
female BM from BM of patients with breast cancer and
had no ability to classify those patients who did or did
not experience a distant metastatic event. However, we
did identify a subset of 17 genes with expression that
after correcting for false discovery, could distinguish
between healthy BM and BM from patients with breast
cancer (Table 4, Fig. 1). Given that the expression of
these genes (1) is frequently associated with biological
processes such as tumor cell proliferation, invasion, and
metastasis; (2) are detectable only in BM from PDX mice
that develop DTCs in their BM and distant organ metas-
tases; and (3) are expressed in patients with breast
cancer, as compared to healthy human BM, we propose
that they are excellent biomarker candidates for future
prospective studies to evaluate whether they can stratify
patients with breast cancer for risk of recurrent disease
based upon detection and classification of BM DTCs.
Discussion
The presence of DTCs in the BM of patients with early-
stage breast cancer identifies patients at high risk of
recurrence [1]. Clinically, it is not clear whether the
DTCs detected in the BM are the sole population of cells
that later develop into metastatic foci, whether they rep-
resent the systemic burden of micrometastatic disease,
or a combination of both. Regardless, clinical data dem-
onstrate that DTCs can persist through chemotherapy
and their presence after chemotherapy identifies a
patient population at very high risk of recurrence, rela-
tive to those patients who clear their DTCs with chemo-
therapy [5, 27, 28]. In spite of these findings, DTC
detection has not become a routine part of breast cancer
patient management, primarily due to the limited num-
ber of targetable biomarkers and lack of a cost-effective,
robust assay for detection which yields molecular infor-
mation [8]. If the DTC phenotype is representative of
the micrometastatic disease that will eventually become
metastatic foci, then eliminating DTCs with targeted
therapeutic approaches could prevent recurrent disease
and result in a survival benefit to patients with breast
cancer. Characterizing these cells is essential as our un-
derstanding of the parallel progression of the primary
tumor and DTCs improves [6, 29].
To date, it has been difficult to study the role of DTCs
in the metastatic cascade and to perform molecular
characterization due to their rarity. However, several
studies have shown that PDX models recapitulate the
molecular phenotype and biological behavior, and are
predictive of clinical response of primary human tumors
Fig. 4 Unsupervised hierarchical cluster analysis of 13,294 gene
transcripts across seven samples of Washington University Human
in Mouse (WHIM17) bone marrow (BM) and corresponding primary
tumor and metastatic lesion. Specific sample numbers are indicated
(see Table 1) and gene expression clusters specifically upregulated in
primary tumor, metastasis, and a subset of BM samples are highlighted
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[9–11, 30]. Several studies have characterized CTCs
using PDX models in breast cancer to better understand
the biology of this process [12, 13] and recently, DTCs
have been reported using PDX models [14]. In the report
by Giuliano et al. [14], DTCs were detected in 62% of
PDX mouse BM.
In this study, we have focused on the combined use of
PDX and patient BM samples to identify unique sets of
gene transcripts that can both detect and classify breast
cancer BM DTCs. A persistent limitation of this
approach is the small number of stable PDX lines that
can be created by implanting primary breast tumor
tissues and, subsequently the number that demonstrate
metastatic behavior. Of the five lines investigated in this
study, only two (WHIM12 and WHIM17) developed
solid organ metastases. Importantly, these were also the
only two lines in which human-specific gene expression
(presumably emanating from DTCs) could be detected
in BM, strongly supporting the idea that DTC
establishment is causal to or at least associated with dis-
tant organ metastasis in PDX mouse models. Further-
more, only one PDX line (WHIM17), derived from a
patient with triple-negative breast cancer, consistently
showed patterns of human gene expression that were
reminiscent of a “mesenchymal-like” phenotype in mul-
tiple animals across multiple passages. It is curious that
WHIM17 was the only tumor xenograft line to persist-
ently propagate BM micrometastasis and it is recognized
that the conclusions on gene expression biomarkers in
human breast cancer BM samples may be necessarily
constrained by this. Recently, Huang et al. [31] reported
that later passages of the WHM17 tumor resembled a
lymphoproliferative malignancy and not breast adeno-
carcinoma, based on RNA sequencing and phosphopro-
teomic studies. Such evolution of genomic features of
PDX tumors when the tumor is propagated in mice has
been reported recently [32]. Nevertheless, data from Li
et al., who also performed molecular profiling of earlier
Table 2 Gene transcripts differentially expressed in the metastasis of WHIM17 lineage mice relative to both control mice and
primary xenograft tumor
Gene symbol Gene name Fold expression p value Targetable
ALB Albumin 97.6 2.77E-08
IGF2 Insulin-like growth factor 2 46.0 1.12E-06
FABP1 Fatty acid binding protein 1 37.0 3.21E-07
GPC3 Glypican 3 24.9 5.78E-09 Yes [38, 39]
DCT Dopachrome tautomerase 21.3 2.15E-07
SPP1 Secreted phosphoprotein 1 16.7 1.18E-07
FGG Fibrinogen gamma chain 16.5 2.56E-07
FGA Fibrinogen alpha chain 15.8 1.67E-07
MAL2 Mal, T-cell differentiation protein 2 14.2 3.75E-08
APOB Apolipoprotein B 12.2 2.62E-07
CPE Carboxypeptidase E 10.7 1.11E-06
BAMBI BMP and activin membrane bound inhibitor 9.6 0.00021247
TYR Tyrosinase 9.4 3.52E-07
BCHE Butyrylcholinesterase 8.8 1.02E-06
CD24 CD24 molecule 8.7 1.55E-05
LEF1 Lymphoid enhancer binding factor 1 8.2 0.0001236
TSPAN8 Tetraspanin 8 6.8 9.95E-06
SERPINA1 Serpin family A member 1 6.2 2.00E-05
CGA Glycoprotein hormones, alpha polypeptide 6.2 7.70E-05
AZGP1 Alpha-2-glycoprotein 1, zinc-binding 6.2 0.00126944
TFF1 Trefoil factor 1 6.2 3.83E-05
HGD Homogentisate 1,2-dioxygenase 5.9 6.49E-05
TYRP1 Tyrosinase related protein 1 5.2 2.68E-05
DSP Desmoplakin 5.1 8.91E-05
C3 Complement C3 5.1 0.00067128
SLPI Secretory leukocyte peptidase inhibitor 5.1 7.24E-05
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passages of this tumor [11] similar to the specimens
used in the current study, suggest that at least initially,
WHIM17 is molecularly characteristic of other “basal-
like” breast cancers.
Using the WHIM17 line, array-based gene expression
profiling was performed to compare primary tumor tis-
sue and a solitary metastatic lesion to multiple BM sam-
ples among different animals and different passages of
the WHIM17 line. By using a human-specific, short-
oligonucleotide array platform (i.e. Affymetrix Gene-
Chips) and comparing WHIM17 BM samples with those
of control mice, it was inferred that the majority of the
13,000+ transcripts identified (Additional file 3: Table
S3) originated from human xenograft-derived tumor
cells. Secondarily, by identifying those transcripts that
were differentially expressed between the primary xeno-
graft tumor and multiple WHIM17 BM samples, a list of
candidate biomarkers of cells with high metastatic po-
tential was created, which was further filtered and
curated based upon association with published manu-
scripts related to metastasis biology (Fig. 1).
Among individual transcripts identified by this analysis
were several genes known to be associated with the
Table 3 Gene transcripts differentially expressed in the bone marrow of WHIM17 lineage mice relative to both control mice and
primary xenograft tumor
Gene symbol Gene name Fold expression p value Targetable
CD53 CD53 molecule 4.1 0.0006062
PTPRC Protein tyrosine phosphatase, receptor type C 3.7 0.00474656
KIR3DL1 Killer cell immunoglobulin like receptor, three Ig domains
and long Cytoplasmic Tail 1
3.2 0.00145097
HBA1 Hemoglobin subunit alpha 1 2.7 0.00117262
MT3 Metallothionein 3 2.7 0.00033581
HBB Hemoglobin subunit beta 2.7 0.00086439
OSM Oncostatin M 2.5 0.00677886
MAP2K6 Mitogen-activated protein kinase kinase 6 2.5 0.00632423
ARHGDIB Rho GDP dissociation inhibitor beta 2.4 0.00115363
SLPI Secretory leukocyte peptidase inhibitor 2.3 0.00071176
DDC Dopa Decarboxylase 2.3 0.00080507 Yes [40]
SSTR4 Somatostatin receptor 4 2.3 0.00058499 Yes [41, 42]
MAPT Microtubule associated protein tau 2.3 0.0010915
HPR Haptoglobin-related protein 2.3 0.00139515
SPN Sialophorin 2.3 0.00092894
HLA-B Major histocompatibility complex, class I, B 2.2 4.27E-05
CISH Cytokine inducible SH2 containing protein 2.2 0.00021425
MST4 Serine/threonine protein kinase 26 2.1 0.0035196
SERPINA5 Serpin family A member 5 2.1 0.00622652
PTPN6 Protein tyrosine phosphatase, non-receptor type 6 2.1 0.00735724
MMP17 Matrix metallopeptidase 17 2.1 0.00493339
CEACAM6 Carcinoembryonic antigen related cell adhesion molecule 6 2.0 0.00179388
Fig. 5 Principal component (PC) analysis (PCA) of 16 bone marrow
(BM) samples from patients with breast cancer (12 without distant
relapse and 4 with distant relapse) and 6 healthy female control BM
samples, based upon a 420-gene signature identified from Washing-
ton University Human in Mouse (WHIM17) BM samples. BRCA
breast cancer
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metastatic process (ALCAM, MALAT1) and EMT
(SNAI1, GSC, FOXC2, SIP1) and breast cancer stem cells
(CD44). Of equal importance, the absence of epithelial-
specific transcripts was a conspicuous feature of these
analyses. While expression of human epithelial genes
such as cytokeratins in the BM have been the corner-
stone for the identification of DTCs as tumor-derived
cells, the absence of these genes is not surprising.
Tumor cells undergo significant transformation in their
morphology and molecular profiles during each stage of
the metastatic process [33]. Only those tumor cells that
successfully adapt to the unfamiliar molecular environ-
ments after being released from the primary tumor into
circulation can survive and grow at a different anatom-
ical location [34]. The BM environment has been shown
to enhance this process through the action of various
stromal cell populations [35]. Therefore, the loss of epi-
thelial and breast-tissue-specific features in these cells
can be attributed to the possible molecular transition
which enables these cells to migrate to and survive in
the BM matrix.
The clinical relevance of the gene expression patterns
identified in WHIM mouse BM was evaluated in the BM
of treatment-naïve patients with breast cancer as well.
Although the xenograft used to create the WHIM17 line
was a “triple negative” tumor, given the small number of
BM gene expression data sets available, we considered
BM samples from all patients, regardless of primary
tumor molecular phenotype, as a single group. A small
number of gene transcripts (Table 4) were differentially
detected in patient BM as compared to healthy female
controls, and the biological role and potential drug
targetability of many of these genes (such as CD44,
CD33, GLIPR1, and HEPB1) has been previously dem-
onstrated. Although we were not able to determine the
number of human DTCs present in the xenograft ani-
mals in the current study, previous studies have demon-
strated that gene-expression-based detection of DTCs in
human bone marrow samples using qRT-PCR can detect
as few as 1 in 1 × 10^6 cells when analyzing 10^7 – 10^8
nucleated cells from a 3-mL BM aspirate, depending
upon the specific gene transcript analyzed [36]. Whether
one or more of these transcripts can be routinely
detected above background expression in normal human
BM, and whether expression of these gene(s) are actually
prognostic for metastatic recurrence are questions cur-
rently being addressed. Although we were unable to
analyze the expression of these genes in the peripheral
blood of xenograft mice, it will also be interesting and
clinically relevant to determine whether the expression
of these genes can be detected in peripheral blood of
patients with breast cancer, possibly providing a less in-
vasive assay to predict early metastatic recurrence.
Our data would argue that DTCs derived from the pri-
mary tumor are mesenchymal-like and express genes
associated with the metastatic process in animals and in
humans. Presence of these cells was limited strictly to
the BM of mice with metastatic tumor development and
they were present in BM at a pre-metastatic time point.
It has been suggested that the parallel progression of pri-
mary and metastatic tumors can occur simultaneously
with early dissemination of cancer cells from the primary
tumor [6, 7, 37]. Since the molecular features of the
tumor cells remain consistent across passages, if DTCs
were a general occurrence rather than associated with
metastatic potential, we would expect to find DTCs in
all animals from the same line irrespective of their meta-
static outcome.
Our results support the use of the PDX mice as a clin-
ically relevant model to examine the molecular features
of DTCs, alteration over time, and whether elimination
of BM DTCs using targeted therapies will result in abro-
gation of metastatic disease development.
Table 4 WHIM bone marrow (BM) gene transcripts with expression
that is statistically greater than background expression in normal
human BM (p< 0.05, corrected for multiple comparisons using the
false discovery (FDR) method)
Gene Gene name Drugs available against target
gene
CD163 CD163 molecule
PDGFC Platelet derived growth
factor C





PF4 Platelet factor 4
CYP1B1 Cytochrome P450 family 1
subfamily B member 1
Yes [43]
EPB41L3 Erythrocyte membrane
protein band 4.1 like 3
MEIS1 Meis homeobox 1
TNFRSF17 TNF receptor superfamily
member 17
DLC1 DLC1 rho GTPase
activating protein
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Conclusion
The presence of DTCs in the BM and its association with
metastatic outcome was observed in the PDX model sys-
tem. Our results provide an experimental support for the
clinical association between DTCs in the BM of patients
with early-stage breast cancer and recurrent disease devel-
opment. We found that DTCs lose epithelial features and
express genes associated with metastases and EMT. More-
over, using this system, we have identified new targetable
genes associated with DTCs. Our data suggest that the
PDX model provides a powerful tool to explore the meta-
static process and the molecular characterization of
DTCs.
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